|drug3979||mouthrinse without bêta-cyclodextrin and citrox Wiki||1.00|
|D011024||Pneumonia, Viral NIH||0.12|
There is one clinical trial.
Given the current lack of effective COVID-19 treatment, it is necessary to explore alternative methods to contain the spread of the infection, focusing in particular on its mode of transmission. The modes of person-to-person transmission of SARS-CoV-2 are direct transmission, such as sneezing, coughing, transmission through inhalation of small droplets, and transmission through contact, such as contact with nasal, oral and eye mucous membranes. SARS-CoV-2 can also be transmitted directly or indirectly through saliva. The use of antiviral mouthrinses may be used as adjunctive therapy.
Description: Quantitative PCR experiments will be performed and a quantitative analysis of the salivary samples will be madeMeasure: Change from Baseline amount of SARS-CoV-2 in salivary samples at 7 days Time: 7 days
Description: Quantitative PCR experiments will be performed and a quantitative analysis of the nasal samples will be madeMeasure: Change from Baseline amount of SARS-CoV-2 virus in nasal samples at 7 days Time: 7 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports